These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24928889)

  • 41. Proliferation assays for estrogenicity testing with high predictive value for the in vivo uterotrophic effect.
    Wang S; Aarts JM; Evers NM; Peijnenburg AA; Rietjens IM; Bovee TF
    J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):98-106. PubMed ID: 22138011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for estrogenicity and anti-estrogenicity: a critical evaluation of an MVLN cell-based transactivation assay.
    Freyberger A; Schmuck G
    Toxicol Lett; 2005 Jan; 155(1):1-13. PubMed ID: 15585354
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endocrine disrupting activities and immunomodulatory effects in lymphoblastoid cell lines of diclofenac, 4-hydroxydiclofenac and paracetamol.
    Klopčič I; Markovič T; Mlinarič-Raščan I; Sollner Dolenc M
    Toxicol Lett; 2018 Sep; 294():95-104. PubMed ID: 29777833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differentiating true androgen receptor inhibition from cytotoxicity-mediated reduction of reporter-gene transactivation in-vitro.
    Marin-Kuan M; Fussell KC; Riederer N; Latado H; Serrant P; Mollergues J; Coulet M; Schilter B
    Toxicol In Vitro; 2017 Dec; 45(Pt 3):359-365. PubMed ID: 28377212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of potential endocrine activity of 2,4-dichlorophenoxyacetic acid using in vitro assays.
    Coady KK; Kan HL; Schisler MR; Gollapudi BB; Neal B; Williams A; LeBaron MJ
    Toxicol In Vitro; 2014 Aug; 28(5):1018-25. PubMed ID: 24815817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERα and ERβ agonists.
    Evers NM; van den Berg JH; Wang S; Melchers D; Houtman R; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
    J Steroid Biochem Mol Biol; 2014 Sep; 143():376-85. PubMed ID: 24923734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioassays for estrogenic activity: development and validation of estrogen receptor (ERalpha/ERbeta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies.
    Li J; Lee L; Gong Y; Shen P; Wong SP; Wise SD; Yong EL
    Assay Drug Dev Technol; 2009 Feb; 7(1):80-9. PubMed ID: 19382890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
    Wilson VS; Bobseine K; Gray LE
    Toxicol Sci; 2004 Sep; 81(1):69-77. PubMed ID: 15166400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
    Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
    Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A robotic MCF-7:WS8 cell proliferation assay to detect agonist and antagonist estrogenic activity.
    Yang CZ; Casey W; Stoner MA; Kollessery GJ; Wong AW; Bittner GD
    Toxicol Sci; 2014 Feb; 137(2):335-49. PubMed ID: 24213142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of mixture effects of endocrine active substances in wastewater using CALUX reporter-gene assays.
    Pannekens H; Gottschlich A; Hollert H; Dopp E
    Int J Hyg Environ Health; 2019 May; 222(4):670-677. PubMed ID: 31129136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SERMs and SARMs: detection of their activities with yeast based bioassays.
    Bovee TF; Thevis M; Hamers AR; Peijnenburg AA; Nielen MW; Schoonen WG
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):85-92. PubMed ID: 19883760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovering small-molecule estrogen receptor α/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency.
    Sun A; Moore TW; Gunther JR; Kim MS; Rhoden E; Du Y; Fu H; Snyder JP; Katzenellenbogen JA
    ChemMedChem; 2011 Apr; 6(4):654-66. PubMed ID: 21365764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A simple heterogeneous one-step assay for screening estrogenic compounds.
    Huovinen T; Rytkönen K; Lamminmäki U; Pellinen T
    Biotechnol Lett; 2013 Jan; 35(1):47-53. PubMed ID: 22986538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integral assessment of estrogenic potentials of sediment-associated samples. Part 1: The influence of salinity on the in vitro tests ELRA, E-Screen and YES.
    Kase R; Hansen PD; Fischer B; Manz W; Heininger P; Reifferscheid G
    Environ Sci Pollut Res Int; 2008 Jan; 15(1):75-83. PubMed ID: 18306891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of nonmonotonic concentration-responses in Tox21 high-throughput screening estrogen receptor assays.
    Shi Z; Xia M; Xiao S; Zhang Q
    Toxicol Appl Pharmacol; 2022 Oct; 452():116206. PubMed ID: 35988584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of methods of detection of water estrogenicity for their use as monitoring tools in a process of estrogenicity removal.
    Blavier J; Songulashvili G; Simon C; Penninckx M; Flahaut S; Scippo ML; Debaste F
    Environ Technol; 2016 Dec; 37(24):3104-19. PubMed ID: 27144327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro characterization of the effectiveness of enhanced sewage treatment processes to eliminate endocrine activity of hospital effluents.
    Maletz S; Floehr T; Beier S; Klümper C; Brouwer A; Behnisch P; Higley E; Giesy JP; Hecker M; Gebhardt W; Linnemann V; Pinnekamp J; Hollert H
    Water Res; 2013 Mar; 47(4):1545-57. PubMed ID: 23305681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endocrine-Disrupting Chemicals (EDCs): In Vitro Mechanism of Estrogenic Activation and Differential Effects on ER Target Genes.
    Li Y; Luh CJ; Burns KA; Arao Y; Jiang Z; Teng CT; Tice RR; Korach KS
    Environ Health Perspect; 2013 Apr; 121(4):459-66. PubMed ID: 23384675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor.
    Nellemann C; Dalgaard M; Holst B; Bonefeld-Jørgensen EC; Vinggaard AM
    Mol Cell Endocrinol; 2005 Jun; 237(1-2):25-35. PubMed ID: 15925091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.